Web Exclusives

Immune checkpoint inhibitors cause rare severe adverse events in patients, but most patients improve with treatment. Read More ›

Patients with NSCLC harboring KRAS G12C have distinct imaging patterns from patients with other NSCLC genetic mutations. Read More ›

A significant increase in clinical trial accruals resulted from dedicating a single employee to screening patients, suggesting a potential paradigm for limited resource settings. Read More ›

To reduce cancer-related cognitive impairment, there may be a benefit to targeting specific inflammatory processes. Read More ›

Quality of social support may impact patients’ disease understanding and should be considered when creating clinical interventions. Read More ›

Differences in patient characteristics, CDK4/6 inhibitor schedule, treatment duration, and discontinuation rates may contribute to differences in outcomes. Read More ›

Practice-directed and targeted interventions enhance detection of risk through genetic counseling and testing. Read More ›

Despite guideline recommendations, a retrospective study found inadequate biomarker testing rates to direct targeted therapy. Read More ›

Researchers highlighted promising research into early-stage diagnostics and therapies for NSCLC harboring the KRAS G12C mutation discussed in a review article. Read More ›

A recent study found that chronic pneumonitis is a rare complication of immune checkpoint inhibitor therapy in patients with NSCLC. Read More ›